InvestorsHub Logo
Followers 72
Posts 6896
Boards Moderated 0
Alias Born 12/07/2011

Re: noretreat post# 203839

Thursday, 11/16/2017 8:36:32 AM

Thursday, November 16, 2017 8:36:32 AM

Post# of 403096
LOL - You could be correct! Interesting language/tone:
___________________________
After unblinding...the Company will initiate an aggressive development plan going forward, including: applying to the Food and Drug Administration (FDA) for Breakthrough Therapy Designation and possibly applying for a similar expedited path in Europe; enhancing oral rinse administration with patient-friendly formulation and packaging; and, dedicating internal resources to Phase 3 trial design planning and execution.

Formal collaboration with pharmaceutical companies that have expressed an interest in partnering Brilacidin-OM may well assist further with expediting the drug candidate’s development timetable. Some of these partnering conversations have matured to the point of potentially structuring mutually beneficial licensing agreements, pending the final Phase 2 study results.
______________________________


IMO - It appears IPIX will use our people and resources to move OM to phase 3? However below they mention licensing agreements and they do mention Europe, so maybe in my unicorn and rainbow world, we will do the Doctor/Admin stuff in preparing for the trial and BP will throw it's money around to make this all go much quicker?

I like the PR though - first time IPIX really puts a line in the sand and really addresses BP and the type of agreements they are discussing.

GO IPIX
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent IPIX News